Search stocks

Find any stock by ticker or company name

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Watchlist
Markets
Calendar
Screener
News
About

SLS - SELLAS Life Sciences Group, Inc.... | Finranks

Home

/

SLS

S

SELLAS Life Sciences Group, Inc. (SLS)

NCM – Real Time Price. Currency in USD

11.77

+0.72 (6.52%)

Market open: Aug 12, 2026, 10:10 AM EDT

11.06

+0.01 (0.06%)

Previous after-hours: Aug 11, 2026, 7:59 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

- Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80 th Event - - 28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Topline Data Expected in Q4 2026 - - Strong Preclinical Indications of Efficacy of SLS009 in Advanced Pancreatic Cancer Resistant to RAS inhibitors, Clinical Development Preparations Ongoing - - $138.3 Million in Cash and Cash Equivalents as of June 30, 2026 - NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. “The second quarter was an important period of execution for SELLAS as we continued to advance both of our lead clinical programs, GPS and SLS009,” said Angelos Stergiou, MD, ScD h.c.

Stock Picks From Seeking Alpha's July 2026 New Analysts

Stock Picks From Seeking Alpha's July 2026 New Analysts

Seeking Alpha welcomed 33 new analysts in July 2026. This article showcases their top picks and investment strategies. Highlighted companies include SELLAS Life Sciences, Chevron, B2Gold, Amazon, and QXO, each with detailed investment theses. Analysts emphasize asymmetric opportunities, event-driven catalysts, balance sheet strength, market structure, and sector-specific growth or risk factors.

SELLAS Life Sciences: The Ownership Structure Has Changed Before The Defining Catalyst

SELLAS Life Sciences: The Ownership Structure Has Changed Before The Defining Catalyst

SELLAS Life Sciences enters its pivotal REGAL readout with a transformed shareholder base, stronger balance sheet, and a new supply structure. Institutional ownership doubled to 36.34%, with average allocation rising, reflecting both new and existing holders increasing stakes ahead of the binary event. Passive and index-linked funds now dominate SLS's register, while multi-strategy and quant funds have exited, reducing volatility-driven trading around the catalyst.

Videos

No Data

There is no data to display

Press releases

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

- Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80 th Event - - 28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Topline Data Expected in Q4 2026 - - Strong Preclinical Indications of Efficacy of SLS009 in Advanced Pancreatic Cancer Resistant to RAS inhibitors, Clinical Development Preparations Ongoing - - $138.3 Million in Cash and Cash Equivalents as of June 30, 2026 - NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. “The second quarter was an important period of execution for SELLAS as we continued to advance both of our lead clinical programs, GPS and SLS009,” said Angelos Stergiou, MD, ScD h.c.